Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 6/7/2024 
Market News

Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 6/7/2024 

TipRanks’ Technical Analysis Screener  gives investors everything they need to find the stocks that fit their unique technical analysis investment strategy. Using the screener, we have identified three stocks that are considered Strong Buys according to both their technical analysis score and Wall Street analysts’ ratings.

Here are this week’s stocks: 

CrowdStrike (NASDAQ:CRWD– CRWD is a cybersecurity company known for its cloud-native endpoint protection platform that detects and prevents threats in real-time. CRWD stock carries a Strong Buy overall technical analysis score. Analysts concur with that sentiment, giving a Strong Buy consensus rating with a 12-month price target that implies an upside of about 18%.

Synopsys (NASDAQ:SNPS) – SNPS is a software company that develops electronic products and applications. The stock has a Strong Buy overall technical analysis score. Likewise, analysts have given SNPS stock a Strong Buy consensus rating, with a 12-month price target indicating about a 13% upside on the stock.

Merck (NYSE:MRK) – This global healthcare company develops pharmaceuticals, vaccines, biologic therapies, and animal health products. The stock has a Strong Buy overall technical analysis score. Likewise, analysts have given the stock a Strong Buy consensus rating, with a 12-month price target indicating about 9% upside potential.

What Is the TipRanks Technical Analysis Score? 

TipRanks’ unique calculation combines the Moving Average score and the Oscillator score to assess a stock’s technical strength or weakness. The score provides a comprehensive view of a stock’s potential price movement based on historical data and technical analysis. 

Disclosure

Related Articles
TheFlyMerck price target lowered to $140 from $145 at Deutsche Bank
TheFlyMerck price target lowered to $130 from $137 at Guggenheim
TheFlyMerck price target lowered to $123 from $130 at Morgan Stanley
Go Ad-Free with Our App